Navigation Links
Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
Date:2/1/2008

CAMBRIDGE, Mass. and CARLSBAD, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that they have received clearance under the Hart-Scott-Rodino Antitrust Improvements Act for their collaboration, which was announced on January 7, 2008. Based on this approval, Genzyme will pay Isis $150 million to purchase five million shares of Isis common stock for $30 per share.

Upon completion of final contracts, Genzyme will pay to Isis an additional up-front cash payment of $175 million for the exclusive licensing of mipomersen. As part of the strategic alliance, Genzyme will develop and commercialize mipomersen, a breakthrough, potential blockbuster lipid-lowering treatment for high risk cardiovascular patients that utilizes Isis' novel antisense technology. Isis will also be eligible to receive milestone and profit sharing payments for mipomersen, which is currently in phase 3 development. In addition, Genzyme will have preferred access to future drugs developed by Isis for CNS and certain rare diseases.

ABOUT GENZYME

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the high
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
2. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
3. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
4. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
5. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
6. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
7. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
8. Genzyme Launches Cholestagel(R) in Europe
9. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
10. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
11. Genzyme Recognized by Scientists as a Top Employer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Sapphire Energy, Inc. , a global leader ... biotechnology veteran James Levine as president, CEO ... Cynthia ,CJ, Warner, who is stepping down from her ... company,s board of directors. "The impact of ... scale algae-based fuels has been tremendous, from overseeing the ...
(Date:7/28/2014)... 28, 2014 “2014 Deep ... Industry” is a professional and in-depth research ... The report introduces Lubricant basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/28/2014)... MD (PRWEB) July 28, 2014 ... personalized medicine, will be exhibiting data and research conducted ... International Spine Intervention Society’s (ISIS) 22nd Annual ... 3rd, at the Hyatt Regency, in Orlando, Florida. ... knowledge and clinical competence of physicians who care for ...
(Date:7/28/2014)... -   JOLT , a leading technology accelerator, announced ... growing portfolio of startups. Next-level tech and boundary-pushing innovation ... JOLT accelerator, and Cohort four is no exception, with ... Since its launch in July 2012, JOLT has produced ... Now at 23 investments, JOLT,s portfolio has an overall ...
Breaking Biology Technology:Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3
... DST Health Solutions, LLC, today launched new versions ... Advance, PowerMHC, PowerMHS and PowerSTEPP. The platforms now support ... & Medicaid Services (CMS). This change—from Version 4010/4010A to ... effective Jan. 1, 2012, as designated by CMS. ...
... I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
... 2010 Cardium Therapeutics (NYSE Amex: CXM ... and Chief Executive Officer will present at the LifeTech ... at 2:00 p.m. Eastern.  The conference will take place ... presentation will not be webcast, investors can access the ...
Cached Biology Technology:HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 2HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 2YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 4YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 5YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 6YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 7YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 8YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 9YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 10YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 11YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 12Cardium to Present at the LifeTech Capital Miami Medical Investors Conference 2
(Date:7/28/2014)... advance the genetic engineering of "fuel" crops for ... by researchers with the U.S. Department of Energy ... led by Lawrence Berkeley National Laboratory (Berkeley Lab). ... enables scientists to identify and characterize the function ... biosynthesis of plant cell walls. , "Our unique ...
(Date:7/28/2014)... to map social connections in prairie dogs have ... light on prairie dog communities that may help ... future conservation efforts. The work was done by ... National Evolutionary Synthesis Center (NESCent). , "Prairie dogs ... plague," says Dr. Jennifer Verdolin, lead author of ...
(Date:7/27/2014)... species of mayfly in the southern Western Ghats, a mountain ... is the first time that any mayfly belonging to the ... , The new species, called Labiobaetis soldani , "is ... contribution to the understanding of the Ephemeroptera of Palaearctic and ... describes the new mayfly in the Journal of Insect ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Social network research may boost prairie dog conservation efforts 2
... combination of the biology of marine mammals, mechanical vibrations ... scientists to better understand the potential harmful effects of ... An international team of researchers from UC ... Zoo in Sweden has developed an approach that integrates ...
... 31, 2010 − A York University doctoral student who discovered ... lab one morning has completed a study that examines 84 ... including the one Jason Gibbs found in downtown Toronto ... identified or described before. Gibbs, expansive study will help ...
... brains, mouth bacteria behaving badly and the hundreds of ... some of the highlights at the Society for General ... annual event takes place on 6-9 September at the ... experts will present cutting-edge scientific research covering a wide ...
Cached Biology News:Researchers develop simulation to better understand the effects of sound on marine life 2Researchers develop simulation to better understand the effects of sound on marine life 3York U researcher finds new bee in downtown Toronto 2
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... 220-240 V, uses floating pin printing technology ... and other biomolecules onto a variety of ... generate high-density arrays with greater than 80,000 ... 57,000 spots per membrane with a capacity ...
... systems are high-precision microarrayers capable of ... samples. VersArray ChipWriter Pro systems set ... and reproducibility to deliver unparalleled quality ... Their modular component design and flexible ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: